Invention Grant
- Patent Title: Heterocyclic compound
-
Application No.: US15769201Application Date: 2016-10-21
-
Publication No.: US10787462B2Publication Date: 2020-09-29
- Inventor: Takatoshi Yogo , Masato Yoshikawa , Morihisa Saitoh , Taisuke Katoh , Tomohiro Seki , Yoshihisa Nakada
- Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Applicant Address: JP Osaka-Shi, Osaka
- Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Current Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Current Assignee Address: JP Osaka-Shi, Osaka
- Agency: Nath, Goldberg & Meyer
- Agent Joshua B. Goldberg; Scott H. Blackman
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@1ebbdd13
- International Application: PCT/JP2016/081373 WO 20161021
- International Announcement: WO2017/069279 WO 20170427
- Main IPC: C07D519/00
- IPC: C07D519/00 ; C07D487/04 ; C07D471/04 ; C07D513/04 ; A61K31/55 ; A61K31/553 ; A61K31/554 ; A61P31/12 ; A61P13/12 ; A61P1/16 ; A61P25/00

Abstract:
The present invention provides a heterocyclic compound having an RIP1 kinase inhibitory action, which is useful for the prophylaxis or treatment of Gaucher's disease, Niemann-Pick disease, inflammatory bowel disease, multiple sclerosis, chronic kidney disease, acute kidney injury, acute hepatic failure, autoimmune hepatitis, hepatitis B, hepatitis C, alcohol steatohepatitis, non-alcohol steatohepatitis and the like.The present invention relates to a compound represented by the following formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
Public/Granted literature
- US20180319819A1 HETEROCYCLIC COMPOUND Public/Granted day:2018-11-08
Information query